An observational study in Bulkamid® for Urinary Incontinence, Urinary Incontinence and Ultrasound, sponsored by Hospices Civils de Lyon. Completed at 1 site in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Hospices Civils de Lyon · Observational
There are currently different treatment options in the management of stress urinary incontinence (SUI). Given a risk of complications inherent to prosthetic reinforcement and numerous current controversies over the use of a synthetic material, other alternatives must be offered to patients. Peri-urethral injections of filler are increasingly becoming part of the therapeutic arsenal. This is a minimally invasive technique carried out under local anesthesia on an outpatient basis.
Peri-urethral injections are currently offered to all patients with stress urinary incontinence, due to sphincter or mixed insufficiency and particularly after suburethral sling failure.
Perineal ultrasound after injection allows you to visualize the positioning of the filler bubbles under the bladder neck. In the event of clinical ineffectiveness associated with poor position of the bubbles, this could be an argument for a 2nd injection. If, on the contrary, the bubbles are well positioned, another technique could be proposed.
983 studies on the registry are indexed under Urinary Incontinence; 180 are open to participants now.
This study's enrollment of 70 is below the median of 120 across 215 observational studies indexed under Urinary Incontinence.
Browse Urinary Incontinence studies →Hospices Civils de Lyon is the lead sponsor of 1,866 studies on the registry; 448 are open to participants now.
Counted across the registry records on this site, refreshed daily.
This study covers all patients who received a first injection of Bulkamid® peri-urethral filler for urinary incontinence between January 2024 and December 2025.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
women over 18
inability to understand the information given
Patients who received a first injection of Bulkamid® for urinary incontinence
Other: Improvement in patients' symptoms
Improvement in patients' symptoms on the PGI-I scale (score 1, 2 or 3) at 7 days after the intervention
improvement in patients' symptoms
improvement in patients' symptoms on the PGI-I scale (score 1, 2, or 3) at 7 days after the intervention
Time frame: 7 days after the intervention
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.